PURPOSE: The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement. METHODS: Patients were treated with HAI paclitaxel 150-275 mg/m(2) (and 15,000 IU heparin intraarterially) every 28 days. A "3 + 3" study design was used. RESULTS: Twenty-six patients were treated (median age, 59 years). Diagnoses were colorectal cancer (n = 10), breast cancer (n = 7), and other (n = 9). The median number of prior therapies was four (range, 0-10). The maximum tolerated dose (MTD) was HAI paclitaxel 225 mg/m(2). Dose-limiting toxicities (DLTs) included Grade 3 neuropathy (1 of 5 patients) at HAI paclitaxel 275 mg/m(2) and Grade 4 thrombocytopenia and neutropenia, and Grade 3 mucositis (1 of 4 patients) at 250 mg/m(2). None of the eight patients treated with HAI paclitaxel 225 mg/m(2) experienced a DLT. The most common toxicities were nausea and peripheral neuropathy. Of 22 patients evaluable for response, 3 (13.6%) patients had SD for ≥4 months (colorectal cancer, n = 1; thyroid cancer, n = 1; and hepatocellular carcinoma, n = 1; duration of response was 4 months, 7.1 months, and 22.2+ months, respectively). CONCLUSION: The MTD of HAI paclitaxel was 225 mg/m(2). This regimen was well tolerated and had antitumor activity in selected patients.
PURPOSE: The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement. METHODS:Patients were treated with HAI paclitaxel 150-275 mg/m(2) (and 15,000 IU heparin intraarterially) every 28 days. A "3 + 3" study design was used. RESULTS: Twenty-six patients were treated (median age, 59 years). Diagnoses were colorectal cancer (n = 10), breast cancer (n = 7), and other (n = 9). The median number of prior therapies was four (range, 0-10). The maximum tolerated dose (MTD) was HAI paclitaxel 225 mg/m(2). Dose-limiting toxicities (DLTs) included Grade 3 neuropathy (1 of 5 patients) at HAI paclitaxel 275 mg/m(2) and Grade 4 thrombocytopenia and neutropenia, and Grade 3 mucositis (1 of 4 patients) at 250 mg/m(2). None of the eight patients treated with HAI paclitaxel 225 mg/m(2) experienced a DLT. The most common toxicities were nausea and peripheral neuropathy. Of 22 patients evaluable for response, 3 (13.6%) patients had SD for ≥4 months (colorectal cancer, n = 1; thyroid cancer, n = 1; and hepatocellular carcinoma, n = 1; duration of response was 4 months, 7.1 months, and 22.2+ months, respectively). CONCLUSION: The MTD of HAI paclitaxel was 225 mg/m(2). This regimen was well tolerated and had antitumor activity in selected patients.
Authors: Chang Jin Yoon; Jin Wook Chung; Jae Hyung Park; Young Ho Yoon; Joon Woo Lee; Seo Young Jeong; Hesson Chung Journal: Radiology Date: 2003-08-27 Impact factor: 11.105
Authors: Bruno Damascelli; Gian Luigi Patelli; Rodolfo Lanocita; Giuseppe Di Tolla; Laura Francesca Frigerio; Alfonso Marchianò; Francesco Garbagnati; Carlo Spreafico; Vladimira Tichà; Caroline Regna Gladin; Mauro Palazzi; Flavio Crippa; Cesare Oldini; Stefano Calò; Alberto Bonaccorsi; Franco Mattavelli; Luigi Costa; Luigi Mariani; Giulio Cantù Journal: AJR Am J Roentgenol Date: 2003-07 Impact factor: 3.959
Authors: Rabih Said; Razelle Kurzrock; Aung Naing; David S Hong; Siqing Fu; Sarina A Piha-Paul; Jennifer J Wheler; Filip Janku; Bryan K Kee; Savita Bidyasar; Joann Lim; Michael Wallace; Apostolia M Tsimberidou Journal: Invest New Drugs Date: 2015-05-21 Impact factor: 3.850
Authors: Jesus Vera-Aguilera; Agop Y Bedikian; Roland L Bassett; Wen-Jen Hwu; Kevin B Kim; Yong Qin; Suzanne Cain; Edwina W Washington; Michael A Davies; Sunil M Patel; Jade Homsi; Nicholas E Papadopoulos; Patrick Hwu; Sapna P Patel Journal: Am J Clin Oncol Date: 2018-11 Impact factor: 2.339
Authors: Alexander Massmann; Thomas Rodt; Steffen Marquardt; Roland Seidel; Katrina Thomas; Frank Wacker; Götz M Richter; Hans U Kauczor; Arno Bücker; Philippe L Pereira; Christof M Sommer Journal: Langenbecks Arch Surg Date: 2015-06-19 Impact factor: 3.445
Authors: Apostolia M Tsimberidou; Yang Ye; Jennifer Wheler; Aung Naing; David Hong; Uchechi Nwosu; Kenneth R Hess; Robert A Wolff Journal: Cancer Chemother Pharmacol Date: 2013-02-03 Impact factor: 3.333